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AbstrACt
Introduction A critical barrier to outcome assessment 
in gender-affirming healthcare is the lack of a specific 
patient-reported outcome measure (PROM). This phase I 
protocol describes an international collaboration between 
investigators in Canada, Denmark, the Netherlands and 
the USA who have coalesced to develop a new PROM (ie, 
the GENDER-Q) to evaluate outcomes of psychological, 
hormonal and surgical gender-affirming treatments.
Methods and analysis This phase I study uses an 
interpretive description approach. Participants aged 16 
years and older seeking any form of gender-affirming 
treatments in centres located in Canada, Denmark, 
the Netherlands and the USA will be invited to take 
part in qualitative interviews. Participants will review 
BREAST-Q and FACE-Q scales hypothesised to contain 
content relevant to specific gender-affirming treatments. 
Interviews will elicit new concepts for additional scale 
development. Each interview will be digitally recorded, 
transcribed and coded. The main outcome of this phase I 
study will be the development of a conceptual framework 
and set of scales to measure outcomes important to 
evaluating gender-affirming treatments. To this end, 
analysis will be used to add/drop/revise items of existing 
scales to achieve content validity. For new concepts, 
coding will assign top-level domains and themes/
subthemes to participant quotes. Codes will be used to 
develop an item pool to inform scale development. Draft 
scales will be shown to transgender and gender diverse 
persons and experts to obtain feedback that will be used 
to refine and finalise the scales. The field-test version of 
the GENDER-Q will be translated by following rigorous 
methods to prepare for the international field-test study.
Ethics and dissemination This study is coordinated 
at McMaster University (Canada). Ethics board approval 
was received from the Hamilton Integrated Ethics Board 
(Canada), the Medical Ethical Committee at VUmc (The 
Netherlands) and Advarra (USA). Findings will be published 
in peer-reviewed journals and presented at national and 
international conferences and meetings.
IntroduCtIon 
The World Professional Association for Trans-
gender Health (WPATH) is an international, 
multidisciplinary association that promotes 
evidence-based care, education, research, 
advocacy and public policy in transgender 
and gender diverse healthcare.1 As WPATH 
policies set the standard for clinical deci-
sion-making in the care of gender diverse 
individuals, the development of patient-cen-
tred outcome tools that measure issues that 
matter to persons from their perspectives was 
called for by the WPATH board in an open 
letter dated May 2018.2 
Gender-affirming treatments are multi-
faceted and can directly impact appearance 
and how individuals function and feel. Such 
treatments have been shown to alleviate 
gender dysphoria and allow people who are 
strengths and limitations of this study
 ► Recruitment of an international sample of partic-
ipants will make it possible to identify concepts 
that are common to people seeking gender-affirm-
ing treatments who live in different countries and 
cultures.
 ► The inclusion of adolescents and adults will enable 
us to identify concepts that are common across age.
 ► To enhance rigour, we adhere to published guide-
lines for determining content validity of existing 
scales, development of new scales and translation/
cultural adaptation of patient-reported outcome 
measures in other languages.
 ► We use a modern psychometric approach to ensure 
GENDER-Q scales are clinically meaningful and sci-
entifically sound.
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transgender or gender diverse to live more comfortably 
with their bodies.3–5 Globally, a rapidly increasing number 
of individuals are seeking gender-affirming care. Concur-
rent with increasing demand, treatments are becoming 
more individualised as the concept of gender is increas-
ingly recognised as existing along a continuum rather 
than binary.6 7 These changes make access to tools to 
enable shared decision-making and the assessment of 
care increasingly important.8
A current barrier to outcome assessment in gender-af-
firming healthcare is the lack of a specific patient-re-
ported outcome measure (PROM) designed to evaluate 
treatment outcomes from the patient perspective. This 
barrier was highlighted in two recent systematic reviews, 
both of which identified that existing PROMs used in 
transgender surgery research are inadequate and called 
for new measures to be developed.9 10 The development 
of a specific PROM is crucial because how someone 
feels and functions before and after gender-affirming 
treatments are concepts best assessed by self-report.11 
Furthermore, outcomes of treatments to alleviate feelings 
of gender incongruence are not measured by generic 
PROMs, including the 36-Item Short Form Health 
Survey,12 which have been used to study gender-affirming 
surgery. Assessing outcomes that matter to patients, such 
as improvements in sexual well-being and body image 
after gender-affirming treatment,13–15 is essential to 
understanding the impact and success of treatments.
Specific scales are needed to cover the full range of 
gender-affirming treatments. Our team recently devel-
oped two scales to measure the appearance of the chest 
and nipples as a supplement to the BODY-Q.16 These 
scales were field-tested in an international (Canada, 
the USA, Denmark, the Netherlands) sample of 739 
participants with different chest indications, including 
gynaecomastia, weight loss and gender-affirming chest 
surgery.17 To develop these scales, we used a modern 
psychometric approach to create clinically meaningful 
and scientifically sound PROM scales with high content 
validity.18 19 We followed international best practice guide-
lines that outline the latest methods for PROM develop-
ment and validation, including guidelines for establishing 
content validity and special considerations for younger 
persons.11 20–23 We followed a three-phased mixed methods 
approach that we previously published24 and is repro-
duced in figure 1. This three-phased approach ensures 
that a new PROM fulfils minimum standards regarding 
reliability and validity as described by the International 
Society for Quality of Life Research25 and the Consen-
sus-based Standards for the Selection of Health Status 
Measurement Instruments.26 27 Briefly, in phase I, using 
qualitative methods, a pool of items was generated. The 
item pool was developed into scales that were shown to 
patients and experts for feedback. This step ensured that 
the content of the new scales comprehensively measured 
outcomes that matter to patients and that instructions, 
response options and items were clear, meaningful and 
unambiguous. In phase II, the scales were field-tested in 
a large international sample. The items in each scale that 
represented the best indicators of outcome were identi-
fied and retained based on their performance against a set 
of psychometric criteria according to Rasch Measurement 
Theory (RMT) analysis.18 In this approach, the qualitative 
phase was crucial because the data were used to create, 
for each scale, a set of items that together mapped out 
a concept of interest on a clinical hierarchy.19 The RMT 
analysis was used to determine if the theorised concepts 
were supported by the field-test data (ie, fit of the data to 
the Rasch model). In phase III, patients are being invited 
to participate in a prospective study to measure change 
following gender-affirming chest surgery. Anchor-based 
and distribution-based methods will be used to examine 
responsiveness.
The following protocol describes an international collab-
oration between investigators in Canada, Denmark, the 
Netherlands and the USA who have coalesced to develop 
a new PROM for evaluating outcomes of gender-affirming 
treatments. The chest and nipples scales represent the first 
step in our programme of research to develop a compre-
hensive set of scales covering all types of gender-affirming 
treatments. Our overarching objective is to build on the 
chest and nipples scales to create a comprehensive PROM 
that is valid and reliable for use in research, quality improve-
ment initiatives and in clinical care with individual patients 
seeking gender diverse healthcare treatments.
MEthods And AnAlysIs
This protocol describes the phase I qualitative study to 
develop a set of independently functioning scales to eval-
uate gender-affirming treatments. We take an applied 
health services research approach called Interpretive 
Description.28 29 This approach aims to generate knowl-
edge relevant to the clinical context and presumes there 
is theoretical knowledge, clinical knowledge and a scien-
tific basis informing a study.
We will conduct a series of interviews that will involve 
two parts. In part 1, we will adapt existing BREAST-Q30 
and FACE-Q31 32 scales hypothesised to have relevant 
content by adding/dropping/revising items as needed. 
In part 2, we will develop scales for new concepts elicited. 
We previously used this two-part approach to establish 
content validity for existing scales and develop new scales 
for the FACE-Q Module for Children, and Young Adults 
described elsewhere.33
To establish content validity of existing scales, we follow 
guidance from the USA Food and Drug Administra-
tion (FDA),11 which recommends that new qualitative 
work, similar to that conducted when developing a PROM, 
can provide evidence of content validity for existing tools 
if patient interviews or focus groups are conducted using 
open-ended methods to elicit participant input. Our team 
will use cognitive interviews to identify relevant content 
within BREAST-Q and FACE-Q scales and open-ended 
interviews to identify new concepts for scale development.
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sample
Participants will be purposively sampled to include a 
maximum variety of age, gender and treatment history 
(psychological, hormonal or surgical). Participants will 
be recruited by someone within the circle of care from 
each participating site or through local support groups. 
Contact details for those who express an interest in the 
study will be passed on to a member of the research team 
to schedule interviews. Participants will be recruited 
from the interdisciplinary clinic for transgender youth 
at McMaster Children’s Hospital (Canada), the McLean 
Clinic (Canada), Women College Hospital (Canada), 
Aalborg University Hospital (Denmark), VU University 
Medical Center (Netherlands), Brownstein & Crane 
Surgical Services (USA) and Align Surgical Associates 
(USA). We do not anticipate problems recruiting the 
necessary participants given the transgender focus and 
high volume of patients at these sites, as well as the 
expressed need for such a measure by the population 
themselves. Interviews will be conducted face-to-face or 
by phone depending on participant preference and logis-
tics for travel.
Part 1: cognitive interviews
Sample size requirements for cognitive interviews are 
variable, with the number of interviews a function of 
the complexity of the PROM and the diversity of the 
population.34 For the review of existing BREAST-Q and 
FACE-Q scales, the FDA document advises the following 
for adapting an existing PROM for a new patient popu-
lation: 'The sample size depends on the completeness of 
the information obtained from analysis of the transcripts. 
Figure 1 Flow diagram showing the multiphase mixed methods protocol for developing the GENDER-Q. Reproduced with 
permission from Wong Riff et al.24 QUAN, quantitative.
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Generally, the number of patients is not as critical as inter-
view quality and patient diversity included in the sample 
in relation to intended clinical trial population charac-
teristics’.11 We will conduct as many cognitive interviews 
as are necessary to establish content validity for existing 
scales. Cognitive interviews will use the ‘think aloud’ 
method with probing to obtain feedback on all aspects of 
each scale.35 36 Cognitive interviews are valuable for iden-
tifying missing content as well as tailoring existing item 
wording, item format and presentation to ensure respon-
dents optimally understand them.
Breasts
Hormonal treatment can lead to breast development 
for some transgender and gender diverse women,37 but 
breast augmentation is often needed. The BREAST-Q is a 
PROM with separate modules for different types of breast 
surgery, including augmentation. The BREAST-Q was 
developed using interview data from 48 women, refined 
through focus groups and interviews involving 88 women, 
and field-tested with 908 presurgery and 1807 postsurgery 
women from Canada and the USA.30 The BREAST-Q has 
close to 50 translations and is used worldwide in clinical 
practice, quality improvement/benchmarking initia-
tives38 39 and research.40 The BREAST-Q has been used 
in research with transgender women41 42 even though its 
development did not include any transgender or gender 
diverse individuals. We will identify relevant content 
within the BREAST-Q augmentation module to provide 
a means to measure satisfaction with breasts for trans-
gender and gender diverse women. We hypothesise that 
some BREAST-Q items will be retained, some will need to 
be modified or dropped, and new items or scales may be 
needed.
Face
Male and female faces differ in obvious ways, especially the 
shape of the forehead, hairline, nose, lips, cheeks, chin, 
jawline, neck and facial hair. For transgender women, 
facial hair removal and facial feminisation surgery provide 
a means to achieve an appearance that is better aligned 
with gender identity.43 The FACE-Q aesthetic module31 32 
has 23 scales that measure the appearance of the face 
and specific facial areas. These scales were developed 
from 50 interviews with patients who were pre-treatment 
or post-treatment for surgical and minimally invasive 
aesthetic treatments and input from 26 experts. Scales 
were refined through 35 cognitive interviews and field-
tested in a sample of 988 cosmetic patients from Canada, 
the USA and the UK. Development of FACE-Q did not 
include people who are transgender or gender diverse. 
To provide scales that can be used to evaluate the effect 
of gender-affirming treatments on facial appearance, we 
will adapt the FACE-Q scales that measure face overall 
and features that differ the most between males/females, 
including the cheeks, chin, forehead, hairline, jawline, 
lips, neck and nose. Cognitive interviews will be used 
to determine whether the scales have content validity 
for people who are transgender or gender diverse. We 
hypothesise that in each scale, some items will be retained, 
some will need to be modified or dropped and new items 
or scales will be needed.
Part 2: concept elicitation
Scale review will be immediately followed by a qualita-
tive interview to elicit new concepts not covered by the 
BREAST-Q and FACE-Q. An interview guide (see box 1) 
will be used to guide the interviews. Topics included 
in the guide were informed by PROMs reviewed in 
two recent systematic reviews of outcomes following 
gender-affirming treatments,9 10 and other phase I plastic 
surgery-specific PROM development studies performed 
by our team. The qualitative interviewer will dynamically 
adapt the interview as needed (eg, for younger partici-
pants) to avoid asking irrelevant questions or questions 
that might be too personal for some to discuss (eg, sexual 
well-being). As interviews progress, the interview guide 
will be iteratively adapted to include new concepts iden-
tified. Sampling and recruitment will continue until the 
point of saturation is reached, that is, no further new 
concepts are elicited from additional interviews.44
data analysis
Both parts of the interviews will be digitally recorded and 
transcribed verbatim. Interviews performed in Denmark 
and the Netherlands will be translated into English prior 
to coding. Data collection and analysis will take place 
concurrently to build on the knowledge gained from 
each interview. Transcripts will be coded using a line-by-
line approach by one member of the research team and 
confirmed by a second member. Codes and data will be 
pasted into an Excel spreadsheet for analysis. For existing 
scales, feedback on the instructions, response options and 
items will be sorted by the scale/item number and exam-
ined to establish content validity for the existing scales by 
making necessary modifications. To develop new scales, 
patient quotes (participant words/phrases) from the 
semi-structured interviews that pertained to any aspect 
of outcome will be categorised into top-level domains 
and themes/subthemes. Qualitative analysis will lead to 
the refinement of a conceptual framework covering the 
concepts that matter to people seeking gender-affirming 
treatments. This framework will be used to guide scale 
development.
The coded material will be used to develop a compre-
hensive item pool within Excel. Items will retain partici-
pant-specific wording to ensure they are easy to understand 
and resonate with patients. As much as possible, positive 
or neutral wording will be adopted for items to minimise 
any negative impact of completing scales. The item pool 
will be analysed and used to develop a comprehensive set 
of independently functioning scales covering key aspects 
of the conceptual framework. Each scale will be assigned 
instructions and the most appropriate time frame and set 
of response options.
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box 1 semi-structured interview guide
Part 1: review of brEAst-Q and FACE-Q scales
Instructions
 ► What are the instructions asking you to do? Please explain in your 
own words.
 ► Is the time frame for responding to the scale appropriate?
 ► Are there any words we should change to make the instructions 
easier?
Items
 ► In your own words, what is this item is asking?
 ► What do you think of when answering this item?
 ► Are any words difficult to understand or offensive?
 ► Was this item hard or easy to answer and why?
 ► Does this item measure an important issue for you?
 ► What do you think about the response choices?
At the end of each scale
 ► In your own words, what is this group of items asking about?
 ► Does this group of items measure an important issue for you?
 ► Are there any items that do not belong with the rest?
 ► Thinking about that group of items, what are we missing?
At the end of the interview
 ► What are your overall thoughts about the questionnaire?
 ► Is there anything we forgot to ask that is important to patients seek-
ing treatment?
 ► Is there anything we should change about our questionnaire?
 ► Is there anything else that you would like to add or comment on?
Part 2: concept elicitation for new scales
Experience of care
 ► Can you tell me about the first time you asked for professional help 
with your gender identity?
 ► Can you tell me about the events that led to your decision to seek 
treatment?
 ► Have you experienced any barriers to obtaining gender-affirming 
treatments?
 ► What are the people like who have cared for you? Probe: helpful, 
friendly, expertise, skill.
 ► What kind of information and advice were you given by healthcare 
providers? Probe: amount, content, interactions.
 ► How could healthcare professionals improve the quality of care pro-
vided to you?
treatments and recovery
 ► What kinds of gender-affirming treatments have you had so far? 
Probe: psychological, hormonal, surgical.
 ► What was the recovery like from surgical treatments? Probe: symp-
toms and impact on activities and daily life.
 ► What was good/bad about each gender-affirming treatment you 
have had?
 ► How happy/satisfied are you with each gender-affirming treatment 
you have had?
 ► Do you plan to have any gender-affirming treatments in the future? 
If yes, which ones?
Appearance
 ► How important is your appearance to you?
 ► To what extent is your appearance aligned with your gender 
identity?
 ► How would you describe your appearance? Probe: face/body/hair/
other.
 ► What do you like/dislike about the appearance? Probe: face/body/
hair/other.
Continued
box 1 Continued
 ► Has your appearance changed with any gender-affirming treat-
ments and how? Probe: face/body/hair/other.
 ► Is there anything else about your appearance that you would like to 
change? Probe: face/body/hair/other.
Voice
 ► How important is how your voice sounds to you?
 ► To what extent is your voice aligned with your gender identity?
 ► How would you describe your voice?
 ► What do you like/dislike about your voice?
 ► How has your voice changed with any gender-affirming treatments 
and how? Probe: do people respond to you differently?
Psychological
 ► How do you generally feel? Probe: negative (anxiety, depression, ir-
ritation) and positive (happy, post-traumatic growth).
 ► Does distress interfere with daily activities and how? Probe: work, 
social, dating.
 ► Has your emotional health changed with any gender-affirming treat-
ments and how?
 ► Which gender-affirming treatments have helped the most in terms 
of emotional well-being?
body image
 ► How do you feel about your face/body/hair/other? Probe: negative 
(self-conscious, uncomfortable, unattractive, abnormal) and positive 
(confident, attractive, normal).
 ► Do you hide or cover parts of your body or face or modify your voice 
to blend in? Probe for how and why.
 ► To what extent is your body image in line with your gender identity?
 ► Has your body image changed with any gender-affirming treat-
ments and how?
 ► Which gender-affirming treatments have helped the most in terms 
of body image?
social
 ► What has it been like for you socially? Probe: school, work, friends, 
family, dating.
 ► Can you describe the kinds of emotional, informational and instru-
mental support you receive from your social network?
 ► Have you experienced any bullying, teasing, abuse, stigmatisation 
or discrimination? Probe: school, work, friends, family, dating and 
coping strategies.
 ► Are there things you want to do in life but do not because of gen-
der-specific issues?
 ► Has your social life changed with any gender-affirming treatments 
and how? Probe: school, work, friends, family, dating.
 ► Which gender-affirming treatments have helped the most in terms 
of your social life?
Physical
 ► To what extent is your physical function aligned with your gender 
identity? Probe: mobility, strength, activities.
 ► How has your physical function changed with the gender-affirming 
treatments? Probe: mobility, strength, activities.
 ► Which gender-affirming treatments have helped the most in terms 
of physical function?
sexual
 ► How important is your sexual life and well-being to you?
 ► How do you feel about your body sexually? Probe: positive (confi-
dent, attractive, normal) and negatives (self-conscious, uncomfort-
able, unattractive, abnormal) and clothed/unclothed.
 ► Can you tell me about any problems or concerns with the sexual life 
related to your gender identity?
Continued
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scale refinement
Refinement of new scales will take place using the same 
approach as described for existing scales, with multiple 
rounds of cognitive interviews using the ‘think aloud’ 
technique.35 36 Participants who took part in the initial 
interviews will be invited to take part in scale refine-
ment. These interviews will be digitally recorded, tran-
scribed and analysed to identify problematic items, 
response options and instruments. Before the final 
round of scale review by participants, the GENDER-Q 
will be shown to experts in transgender and gender 
diverse healthcare for feedback. The goal is to ensure 
that we have not overlooked any important concepts. 
We will design a survey using Research Electronic Data 
Capture, a secure web-based data collection system.45 
Experts from around the world identified from our 
professional circles will be invited by email to provide 
feedback on existing content and to suggest missing 
content. Any changes suggested by experts will be 
reviewed in a final round of participant interviews to 
ensure that the field-test version of the GENDER-Q is 
composed of a set of scales that are easy to understand 
and comprehensively measure outcomes that matter to 
transgender and gender diverse people.
translations
In preparation for an international field-test, the 
GENDER-Q will be translated into languages needed by 
participating sites. We will follow the methodology that 
was recommended for translations of PROMs in the field 
of plastic surgery, which we already applied to other 
PROMs developed by members of our team (eg, BODY-
Q,46 CLEFT-Q47). This approach is in accordance with 
the International Society for Pharmacoeconomics and 
Outcomes Research48 and the World Health Organiza-
tion49 recommendations for linguistic validations. Briefly, 
the translation will follow a rigorous process that involves 
two independent forward and one backward translation, 
an expert panel meeting and a series of cognitive patient 
interviews. The goal is to obtain a culturally adapted and 
equivalent translation of the GENDER-Q that is easily 
understood in the target language.
subsequent phases
We will apply for grant funding to conduct phase II 
and III studies. The phase II field-test study will involve 
recruitment of a large international sample of partici-
pants. We will use the data collected to refine and validate 
GENDER-Q scales using RMT analysis.18 Our goal will be 
to identify the subset of items for each scale that represent 
the best indicators of outcome resulting in shorter clini-
cally meaningful and scientifically sound scales. Items for 
retention will be identified based on their performance 
against a set of psychometric tests that are described in 
detail elsewhere.19 Once developed and validated, we 
will conduct further psychometric research to determine 
each scales’ ability to measure clinical change following 
gender-affirming treatments (phase III studies).
Patient and public involvement
Our patient-oriented approach engages transgender 
and gender diverse people and healthcare providers in 
all stages of our research as experts and research team 
members whose input is crucial to the design of the study 
and development of content for GENDER-Q scales. All 
participants in the initial qualitative interviews will be 
invited to continue to collaborate in our study by taking 
part in scale refinement interviews where they can 
provide feedback on our findings and help to refine the 
final set of scales. At the VUmc hospital, regular meet-
ings for transgender individuals are held to update them 
on the outcomes of conducted research. For all partici-
pants, we will disseminate feedback in the form a news-
letter with links and information about presentations and 
publications.
EthICs
Each participant will provide written and oral consent 
before participating. Given that transgender and gender 
diverse people can experience gender dysphoria and 
report higher than average rates of depression and suicide 
ideation,50–54 it could prove upsetting to participants to 
talk about their experiences. As necessary, we will provide 
a list of support services within the city and put patients 
in touch with a healthcare provider at the recruiting site 
to obtain support. Patient data will be de-identified at the 
transcription phase. All data will be kept secure and confi-
dential following institution rules for data storage.
dIssEMInAtIon
To ensure uptake, once the GENDER-Q is developed, 
it will be made available free of charge to all non-profit 
users. Our team will seek to raise awareness and 
promote its use among stakeholders including patients, 
researchers, healthcare practitioners, decision-makers 
and policy-makers. To this end, our dissemination initia-
tives will include face-to-face interactions as well as elec-
tronic and hard-copy media, all effective strategies for 
research uptake.55 We will seek out opportunities to 
box 1 Continued
 ► In what ways has gender-affirming treatment changed your genita-
lia? Probe: appearance, function.
 ► Has your sexual life changed with any gender-affirming treatment 
and how? Probe: frequency, quality, drive, arousal.
 ► Which gender-affirming treatments have helped the most in terms 
of your sexual life?
Additional questions
 ► Can you describe any other concerns or issues you experienced that 
we have not already covered?
 ► Thinking back over this interview, what are the most/least important 
issues that we have talked about?
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deliver presentations at national and international meet-
ings. We will publish findings for the GENDER-Q in high 
impact journals that we know to be valued and read by 
our target audiences. Finally, we will use social media (eg, 
Twitter, Instagram) to spread awareness of our work to 
our network of followers.
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